Onco-Innovations Partners with Nanosoft Polymers for ONC010 Development

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ), a Canadian-based company dedicated to cancer research and treatment, has announced a significant step forward in the development of its oncology candidate, ONC010. The company has entered into a non-binding letter of intent with Nanosoft Polymers to negotiate a services agreement aimed at supporting the development of its exclusively licensed PNKP inhibitor technology. The proposed collaboration will focus on polymer process development, analytical characterization, formulation optimization, and manufacturing planning activities, all of which are critical for advancing ONC010 toward clinical and regulatory milestones. This partnership underscores Onco-Innovations' commitment to pioneering innovative solutions for solid tumours through its patented technology.

In addition to this strategic collaboration, Onco-Innovations has appointed Dave Antony as vice president of corporate finance. With over 35 years of experience in financial planning, reporting, corporate governance, and public company advisory services, including leadership roles with TSX Venture Exchange advisory committees, Antony is expected to support the company’s oncology-focused growth strategy and enhance engagement with investors and stakeholders. This move reflects the company's focus on strengthening its financial leadership as it progresses its pipeline.

The full press release is available at https://ibn.fm/JB4rY. Onco-Innovations continues to make strides in the oncology space, leveraging exclusive licenses and expert hires to advance its mission of preventing and treating cancer. For more information, visit https://oncoinnovations.com/. This news was disseminated by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides corporate communications solutions and enhanced press release distribution to a wide audience.